Ice Score Car T

Introduction to Ice Score Car T

Let's dive into the details surrounding Ice Score Car T. Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) covers the etiology, risk factors, symptoms, assessment with the ...

Ice Score Car T Comprehensive Overview

Presented by Harpreet Sandhu, PharmD, MS on October 18, 2022. Thursday, May 21, 2026. In this video, Rose Ellard, MSc, Kings College Hospital NHS Foundation Trust, London, UK, gives an overview of adverse effects ...

In this webinar for patients and caregivers, Dr. Yvonne Chen, a CRI Lloyd J. Old STAR, discusses how she has developed new ...

Summary & Highlights for Ice Score Car T

In this video, Daniela Beyer-Bontognali, RN, University Hospital of Zurich, Zurich, Switzerland, discusses her presentation at the ...
Grace Ferri, MD, Beth Israel Deaconess Medical Center, Boston, MA, comments on the need for a modified neurotoxicity metric in ...
Karl Kilgore, PhD, Avalere Health, An Inovalon Company, Bowie, MD, discusses the real-world data study describing the ...
Dr Jeremy Abramson, MD, from the Massachusetts General Hospital, Boston, MA, gives us a detailed presentation of progress in ...
CAR T

That wraps up our extensive overview of Ice Score Car T.

Recent Articles

Module 2: Toxicity Assessment and Management | ICANS

Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) covers the etiology, risk factors, symptoms, assessment with the ...

CAR-T Toxicities: CRS and ICANS

Presented by Harpreet Sandhu, PharmD, MS on October 18, 2022.

Optimal Managment of CRS and ICANS with CAR T Cell Therapy

Thursday, May 21, 2026.

CAR-T: symptoms and their assessment

In this video, Rose Ellard, MSc, Kings College Hospital NHS Foundation Trust, London, UK, gives an overview of adverse effects ...

Nursing perspectives: a look at ICANS in CAR-T

In this video, Daniela Beyer-Bontognali, RN, University Hospital of Zurich, Zurich, Switzerland, discusses her presentation at the ...

The non-native English speaker ICE (NICE) score for patients with myeloma receiving cellular therapy

Grace Ferri, MD, Beth Israel Deaconess Medical Center, Boston, MA, comments on the need for a modified neurotoxicity metric in ...

CAR-T for NHL: a first real-world study

Karl Kilgore, PhD, Avalere Health, An Inovalon Company, Bowie, MD, discusses the real-world data study describing the ...

Results of the TRANSCEND study of CAR T Cell Product JCAR017 in patients with R/R aggressive B-NHL

Dr Jeremy Abramson, MD, from the Massachusetts General Hospital, Boston, MA, gives us a detailed presentation of progress in ...

CAR T-Cell Therapy: ASCO’s 2018 Advance of the Year

CAR T

Engineering Better CAR T Cells: An Interview with CRI STAR Yvonne Chen, PhD

In this webinar for patients and caregivers, Dr. Yvonne Chen, a CRI Lloyd J. Old STAR, discusses how she has developed new ...

Patient selection for CAR-T in ALL

Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, Philadelphia, PA, explains the selection process and criteria ...

Impact of prior lines of therapy before ASCT and CAR-T on aggressive NHL

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, talks on the impact of prior lines of therapy before autologous stem cell transplant ...

Updated safety & durability results for CAR-T lisocabtagene maraleucel in NHL

Jeremy Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses updated results from the ...